These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15793938)

  • 1. Use of implantable cardioverter-defibrillators for prevention of sudden death in patients at high risk for ventricular arrhythmia.
    Technol Eval Cent Assess Program Exec Summ; 2005 Mar; 19(19):1-6. PubMed ID: 15793938
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of implantable cardioverter-defibrillators for prevention of sudden death in patients at high risk for ventricular arrhythmia.
    TEC Bull (Online); 2002 Jul; 19(2):29-36. PubMed ID: 12166476
    [No Abstract]   [Full Text] [Related]  

  • 3. Microvolt T-wave alternans testing to risk stratify patients being considered for ICD therapy for primary prevention of sudden death.
    Blue Cross Blue Shield Association Technology Evaluation Center
    Technol Eval Cent Assess Program Exec Summ; 2007 May; 21(14):1-3. PubMed ID: 17557413
    [No Abstract]   [Full Text] [Related]  

  • 4. Microvolt T-wave alternans testing to risk stratify patients being considered for ICD therapy for primary prevention of sudden death.
    Technol Eval Cent Assess Program Exec Summ; 2005 Oct; 20(9):1-3. PubMed ID: 16267944
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Special report: cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population.
    Technol Eval Cent Assess Program Exec Summ; 2004 Apr; 19(3):1-2. PubMed ID: 15314827
    [No Abstract]   [Full Text] [Related]  

  • 7. The Economics of ICDs.
    Jauhar S; Slotwiner DJ
    N Engl J Med; 2004 Dec; 351(24):2542-4. PubMed ID: 15590958
    [No Abstract]   [Full Text] [Related]  

  • 8. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
    Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
    Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary prevention of sudden cardiac death].
    Reek S; Geller JC; Klein HU
    Dtsch Med Wochenschr; 2001 Apr; 126(15):435-8. PubMed ID: 11347006
    [No Abstract]   [Full Text] [Related]  

  • 10. Preventing sudden death: implantable cardioverter-defibrillators in elderly cardiac patients.
    Groeneveld PW
    LDI Issue Brief; 2008; 13(6):1-4. PubMed ID: 18613344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from neutral ICD trials.
    Nisam S; Breithardt G
    Europace; 2006 Jun; 8(6):393-7. PubMed ID: 16670114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
    Coats AJ
    Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The "clinical cost" of implantable cardioverter-defibrillators in the primary prevention of sudden cardiac death should not restrict their use].
    Francia P; Cappato R
    G Ital Cardiol (Rome); 2011 May; 12(5):379-82; discussion 382. PubMed ID: 21593958
    [No Abstract]   [Full Text] [Related]  

  • 14. Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?
    Katritsis DG; Josephson ME
    Europace; 2012 Jun; 14(6):787-94. PubMed ID: 22308081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The "clinical cost" of implantable cardioverter-defibrillators in the primary prevention of sudden cardiac death is underestimated].
    Disertori M
    G Ital Cardiol (Rome); 2011 May; 12(5):374-8; discussion 378. PubMed ID: 21593957
    [No Abstract]   [Full Text] [Related]  

  • 16. [Variables of arrhythmia risk in relation to pacemaker and implantable defibrillator].
    Solano A; Oddone D; Croci F; Donateo P; Puggioni E; Brignole M
    Ital Heart J Suppl; 2001 Dec; 2(12):1303-7. PubMed ID: 11838352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sudden cardiac death and implantable cardioverter-defibrillators.
    Turakhia MP
    Am Fam Physician; 2010 Dec; 82(11):1357-66. PubMed ID: 21121520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials update: sudden cardiac death prevention by implantable device therapy.
    Finch NJ; Leman RB
    Crit Care Nurs Clin North Am; 2005 Mar; 17(1):33-8, x. PubMed ID: 15749399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death.
    Klein MH; Gold MR
    Cardiol Clin; 2008 Aug; 26(3):419-31, vi-vii. PubMed ID: 18538188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
    Nanthakumar K; Epstein AE; Kay GN; Plumb VJ; Lee DS
    J Am Coll Cardiol; 2004 Dec; 44(11):2166-72. PubMed ID: 15582314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.